Related Experiment Video

Updated: Aug 18, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Conditional regulation of the human CYP4X1 and CYP4Z1 genes

Uzen Savas1, Mei-Hui Hsu, Keith J Griffin

  • 1Division of Biochemistry, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, USA.

Archives of Biochemistry and Biophysics
|March 31, 2005
PubMed

Insights

Two novel human cytochrome P450 genes, CYP4X1 and CYP4Z1, show distinct tissue expression patterns. Their gene expression is regulated by peroxisome proliferator-activated receptor-alpha (PPARα) and steroid hormone receptors.

Area of Science:

  • Genomics
  • Molecular Biology
  • Pharmacology

Background:

  • The human genome contains numerous cytochrome P450 (CYP) genes involved in drug metabolism and signaling.
  • Identification of novel CYP subfamilies is crucial for understanding their biological roles and potential therapeutic implications.

Purpose of the Study:

  • To identify and characterize two new human CYP subfamilies, CYP4X1 and CYP4Z1.
  • To investigate the tissue distribution and regulatory mechanisms of CYP4X1 and CYP4Z1 gene expression.

Main Methods:

  • Human genome and Expressed Sequence Tags database mining for novel CYP genes.
  • Isolation of partial cDNAs and tissue distribution analysis using quantitative methods.
  • Hormonal induction studies in cell lines (T47-D, MCF-7) and receptor antagonist assays.
  • Analysis of gene transcription regulation by peroxisome proliferator-activated receptor-alpha (PPARα) in HepG2 cells.

Main Results:

  • CYP4X1 and CYP4Z1 subfamilies were identified in the human genome.
  • CYP4X1 showed predominant expression in trachea and aorta.
  • CYP4Z1 was preferentially expressed in mammary tissue and its expression was induced by dexamethasone and progesterone via respective receptors.
  • PPARα activation significantly induced CYP4X1 mRNA levels in HepG2 cells.

Conclusions:

  • CYP4X1 and CYP4Z1 exhibit selective tissue expression patterns.
  • PPARα activation is implicated in the regulation of CYP4X1 transcription.
  • Glucocorticoid and progesterone receptors play a role in the activation of CYP4Z1 gene expression.

More Related Videos

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes09:44

High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes

Published on: March 3, 2015

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...